March 10, 2021 -- Thermo Fisher Scientific plans to invest up to $600 million to expand its bioprocessing production capabilities through 2022.
The funds are expected to more than double the company's current manufacturing capacity and support biopharma customers as they ramp up to meet short-term demands related to COVID-19, as well as long-term efforts to develop new vaccines and biologics for other conditions.
Thermo Fisher's single-use technologies business is expanding capacity at sites in Logan, UT, Millersburg, PA, Cramlington, U.K., Singapore, and Suzhou, China. Additional investment at its site in Santa Clara, CA, will expand bioprocessing equipment and automation capacity.
Also, the company will expand its POROS resin manufacturing site in Bedford, MA and open a new 85,000-sq-ft manufacturing facility in Chelmsford, MA. Finally, it will expand production of Gibco cell culture media, supplements, and processing liquids by expanding capacity at its sites in Grand Island, NY, Miami, and Inchinnan, Scotland.